The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), is recommending that Alexion Pharmaceuticals‘ Ultomiris (ravulizumab-cwvz) be approved to treat children and adults with atypical hemolytic uremic syndrome (aHUS). A final decision from the European Commission is expected in the…
Scientists have discovered, in a Chinese patient, new mutations in the DGKE gene that can cause atypical hemolytic uremic syndrome (aHUS), a case report shows. These new mutations expand current knowledge of this gene in the context of aHUS, and highlight potential racial differences in DGKE genetic…
Treatment with Soliris (eculizumab) led to successful resolution of atypical hemolytic uremic syndrome (aHUS) that was triggered by inflammatory bowel disease (IBD), a study of two cases has found. The study, “Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel…
Get regular updates to your inbox.